GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Total Long-Term Liabilities

Biogen (BSP:BIIB34) Total Long-Term Liabilities : R$40,495 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Biogen's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was R$40,495 Mil.

Biogen Total Long-Term Liabilities Historical Data

The historical data trend for Biogen's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Total Long-Term Liabilities Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37,069.38 52,427.58 48,741.85 41,401.42 42,192.67

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40,608.85 36,450.32 42,923.23 42,192.67 40,494.74

Biogen Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Biogen Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Total Long-Term Liabilities
Comparable Companies
OGN AMRN SCLX MIRA GILD BMY AMGN LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines